Clinical Study of the Role of Differential Blood Count as a Pretreatment Diagnosis for Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Abstract

The study employed simple differential blood count assessing clinical prognosis index at diagnosis of DLBCL patients. Each patient’s prognostic performance status was computed using absolute neutrophils/absolute lymphocytes(ANC/ALC), absolute lymphocytes/absolute monocyte (ALC/AMC), and absolute platelet/absolute lymphocytes APC/ALC) respectively, and then compared to preexisting parameters IPI, ECOG-PS, KI-67% protein expression, LDH, gender, bone marrow infiltration, and tumor location using ROC curves to determine the sensitivity and specificity threshold of each CBC performance index and survival analysis to estimate 5-year PFS and OS. The study showed that NLR compared to LDH at NLR ≥ 3.50 correlates to an increase in LDH >230UI/L, ECOG-PS score 2-4, increase in nodal tumor location, and elevation in cell proliferation at ki-67% protein expression (≥20%) at diagnosis exhibit poor prognosis to R-CHOP chemotherapy. Our results also demonstrated that LMR≤2.50 was associated with ECOG-PS score 2-4, increased number of extranodal tumor locations, in comparison with gender female participants had high sensitivity 60%, also low score LMR≤ 2.50 correspond to IPI score 3-5 among DLBCL patients. Our results further revealed that Pretreatment PLR≥150 at diagnosis correlates with LDH>230UI/L, and an ECOG-PS score of 2-4 in DLBCL patients.